Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation

European Journal of Immunology

Volumn 44, Issue 12, 2014, Pages 3508-3521

  Mishto, Michele ^a,b   Liepe, Juliane ^c   Textoris Taube, Kathrin ^a   Keller, Christin ^a   Henklein, Petra ^a   Weberruß, Marion ^d   Dahlmann, Burkhardt ^a   Enenkel, Cordula ^d   Voigt, Antje ^a,e   Kuckelkorn, Ulrike ^a   Stumpf, Michael P H ^c   Kloetzel, Peter M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Antigen presentation; Immunoproteasome; MHC class I restricted epitopes; Proteasome; Proteolysis

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; IMMUNOPROTEASOME; ISOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; ISOENZYME; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN MOTIF; SPLEEN CELL; ANIMAL; ENZYME SPECIFICITY; GENETICS; IMMUNOLOGY; MUTANT MOUSE STRAIN; PHYSIOLOGY; TRANSFORMED CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE, TRANSFORMED; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; ISOENZYMES; MICE; MICE, MUTANT STRAINS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SUBSTRATE SPECIFICITY;

EID: 84924325954     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444902     Document Type: Article

References (55)

1. Bellavista, E., Andreoli, F., Parenti, M. D., Martucci, M., Santoro, A., Salvioli, S., Capri, M. et al., Immunoproteasome in cancer and neuropathologies: a new therapeutic target? Curr. Pharm. Des. 2013. 19: 702-718.
2. Dick, T. P., Nussbaum, A. K., Deeg, M., Heinemeyer, W., Groll, M., Schirle, M., Keilholz, W. et al., Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 1998. 273: 25637-25646.
3. Schechter, I. and Berger, A., On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967. 27: 157-162.
4. Huber, E. M., Basler, M., Schwab, R., Heinemeyer, W., Kirk, C. J., Groettrup, M. and Groll, M., Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012. 148: 727-738.
5. Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N. et al., Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J. Biochem. 1994. 115: 257-269.
6. Goldberg, A. L. and Rock, K. L., Proteolysis, proteasomes and antigen presentation. Nature 1992. 357: 375-379.
7. Gaczynska, M., Rock, K. L., Spies, T. and Goldberg, A. L., Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl. Acad. Sci. USA 1994. 91: 9213-9217.
8. Falk, K. and Rotzschke, O., Consensus motifs and peptide ligands of MHC class I molecules. Semin. Immunol. 1993. 5: 81-94.
9. Momburg, F., Ortiz-Navarrete, V., Neefjes, J., Goulmy, E., van deWal, Y., Spits, H., Powis, S. J. et al., Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 1992. 360: 174-177.
10. Fehling, H. J., Swat, W., Laplace, C., Kuhn, R., Rajewsky, K., Muller, U. and von Boehmer, H., MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994. 265: 1234-1237.
11. Vigneron, N. and Van den Eynde, B. J., Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr. Opin. Immunol. 2011. 24: 84-91.
12. Toes, R. E., Nussbaum, A. K., Degermann, S., Schirle, M., Emmerich, N. P., Kraft, M., Laplace, C. et al., Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 2001. 194: 1-12.
13. Tenzer, S., Stoltze, L., Schonfisch, B., Dengjel, J., Muller, M., Stevanovic, S., Rammensee, H. G. et al., Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J. Immunol. 2004. 172: 1083-1091.
14. de Verteuil, D., Muratore-Schroeder, T. L., Granados, D. P., Fortier, M. H., Hardy, M. P., Bramoulle, A., Caron, E. et al., Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol. Cell. Proteomics 2010. 9: 2034-2047.
15. Kincaid, E. Z., Che, J. W., York, I., Escobar, H., Reyes-Vargas, E., Delgado, J. C., Welsh, R. M. et al., Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat. Immunol. 2011. 13: 129-135.
16. Basler, M., Youhnovski, N., Van Den Broek, M., Przybylski, M. and Groettrup, M., Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 2004. 173: 3925-3934.
17. + T cell responses. J. Immunol. 2013. 191: 52-59.
18. Dahlmann, B., Ruppert, T., Kuehn, L., Merforth, S. and Kloetzel, P. M., Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 2000. 303: 643-653.
19. Groettrup, M., Kirk, C. J. and Basler, M., Proteasomes in immune cells: more than peptide producers? Nat. Rev. Immunol. 2010. 10: 73-78.
20. Mishto, M., Goede, A., Taube, K. T., Keller, C., Janek, K., Henklein, P., Niewienda, A. et al., Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol. Cell. Proteomics 2012. 11: 1008-1023.
21. Sixt, S. U., Alami, R., Hakenbeck, J., Adamzik, M., Kloss, A., Costabel, U., Jungblut, P. R. et al., Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndrome. Mediators Inflamm. 2012. 2012: 204250.
22. Kuckelkorn, U., Frentzel, S., Kraft, R., Kostka, S., Groettrup, M. and Kloetzel, P. M., Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur. J. Immunol. 1995. 25: 2605-2611.
23. Zoeger, A., Blau, M., Egerer, K., Feist, E. and Dahlmann, B., Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin. Chem. 2006. 52: 2079-2086.
24. Mishto, M., Santoro, A., Bellavista, E., Sessions, R., Textoris-Taube, K., Dal Piaz, F., Carrard, G. et al., A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol. Chem. 2006. 387: 417-429.
25. Muchamuel, T., Basler, M., Aujay, M. A., Suzuki, E., Kalim, K. W., Lauer, C., Sylvain, C. et al., A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009. 15: 781-787.
26. Driscoll, J., Brown, M. G., Finley, D. and Monaco, J. J., MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993. 365: 262-264.
27. Mishto, M., Bellavista, E., Ligorio, C., Textoris-Taube, K., Santoro, A., Giordano, M., D'Alfonso, S. et al., Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PLoS One 2010. 5: e9287.
28. Basler, M., Lauer, C., Moebius, J., Weber, R., Przybylski, M., Kisselev, A. F., Tsu, C. et al., Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J. Immunol. 2012. 189: 1868-1877.
29. Skipper, J. C., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H. et al., Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 1999. 82: 669-677.
30. Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B. et al., Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000. 12: 107-117.
31. Chapiro, J., Claverol, S., Piette, F., Ma, W., Stroobant, V., Guillaume, B., Gairin, J. E. et al., Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 2006. 176: 1053-1061.
32. Cardinaud, S., Consiglieri, G., Bouziat, R., Urrutia, A., Graff-Dubois, S., Fourati, S., Malet, I. et al., CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. PLoS Pathog. 2011. 7: e1002049.
33. Knuehl, C., Spee, P., Ruppert, T., Kuckelkorn, U., Henklein, P., Neefjes, J. and Kloetzel, P. M., The murine cytomegalovirus pp89 immunodominant H-2Ld epitope is generated and translocated into the endoplasmic reticulum as an 11-mer precursor peptide. J. Immunol. 2001. 167: 1515-1521.
34. Peters, B., Janek, K., Kuckelkorn, U. and Holzhutter, H. G., Assessment of proteasomal cleavage probabilities from kinetic analysis of timedependent product formation. J. Mol. Biol. 2002. 318: 847-862.
35. Tenzer, S., Peters, B., Bulik, S., Schoor, O., Lemmel, C., Schatz, M. M., Kloetzel, P. M. et al., Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 2005. 62: 1025-1037.
36. Niedermann, G., Grimm, R., Geier, E., Maurer, M., Realini, C., Gartmann, C., Soll, J. et al., Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J. Exp. Med. 1997. 186: 209-220.
37. + T cells. J. Immunol. 2006. 177: 6238-6244.
38. Kniepert, A. and Groettrup, M., The unique functions of tissue-specific proteasomes. Trends Biochem. Sci. 2013. 39: 17-24.
39. Orlowski, M., Cardozo, C. and Michaud, C., Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 1993. 32: 1563-1572.
40. Blackburn, C., Barrett, C., Blank, J. L., Bruzzese, F. J., Bump, N., Dick, L. R., Fleming, P. et al., Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg. Med. Chem. Lett. 2010. 20: 6581-6586.
41. Princiotta, M. F., Finzi, D., Qian, S. B., Gibbs, J., Schuchmann, S., Buttgereit, F., Bennink, J. R. et al., Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003. 18: 343-354.
42. Cascio, P., Hilton, C., Kisselev, A. F., Rock, K. L. and Goldberg, A. L., 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 2001. 20: 2357-2366.
43. Yewdell, J. W., Reits, E. and Neefjes, J., Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 2003. 3: 952-961.
44. Sijts, A. J., Ruppert, T., Rehermann, B., Schmidt, M., Koszinowski, U. and Kloetzel, P. M., Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J. Exp. Med. 2000. 191: 503-514.
45. Chen, W., Norbury, C. C., Cho, Y., Yewdell, J. W. and Bennink, J. R., Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 2001. 193: 1319-1326.
46. Basler, M., Moebius, J., Elenich, L., Groettrup, M. and Monaco, J. J., An altered T cell repertoire in MECL-1-deficient mice. J. Immunol. 2006. 176: 6665-6672.
47. Deol, P., Zaiss, D. M., Monaco, J. J. and Sijts, A. J., Rates of processing determine the immunogenicity of immunoproteasome-generated epitopes. J. Immunol. 2007. 178: 7557-7562.
48. + T cell responses. J. Immunol. 2006. 177: 7680-7688.
49. + T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. USA 2006. 103: 994-999.
50. Mishto, M., Luciani, F., Holzhutter, H. G., Bellavista, E., Santoro, A., Textoris-Taube, K., Franceschi, C. et al., Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J. Mol. Biol. 2008. 377: 1607-1617.
51. Mishto, M., Bonafe, M., Salvioli, S., Olivieri, F. and Franceschi, C., Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp. Gerontol. 2002. 37: 301-308.
52. Riberdy, J. M. and Cresswell, P., The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J. Immunol. 1992. 148: 2586-2590.
53. Van Kaer, L., Ashton-Rickardt, P. G., Eichelberger, M., Gaczynska, M., Nagashima, K., Rock, K. L., Goldberg, A. L. et al., Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994. 1: 533-541.
54. Parlati, F., Lee, S. J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J. B., Micklem, D. R. et al., Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009. 114: 3439-3447.
55. Liepe, J., Mishto, M., Textoris-Taube, K., Janek, K., Keller, C., Henklein, P., Kloetzel, P. M. et al., The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comput. Biol. 2010. 6: e1000830.